Luveltamab Tazevibulin (STRO-002) in Infants and Children < 12 Years of Age with Relapsed/Refractory CBFA2T3::GLIS2 AML (clinicaltrials.gov) - Nov 7, 2024 - P1/2 | N=24 | Not yet recruiting | Sponsor: Sutro Biopharma, Inc.
New P1/2 trial • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology
|